rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)
A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, completed.
Overview
rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC) is a phase 3 interventional study registered as NCT04964284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 390 participants recorded, started 2021-10-06 and reaching its primary completion in 2026-01-31. Interventions recorded: rhTSH, Radioiodine (131I). Conditions recorded: Differentiated Thyroid Cancer.
Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialComparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Shares Thyrotropin alfa, Suzhou Zelgen Biopharmaceuticals, Thyroid cancer and the tag pipeline.
- TrialA New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
- TrialStudy of ZGGS18 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS34 in Participants With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.